Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
430 stopped studies mapped to Liver Carcinoma and descendants · 93% state a reason
Over the 430 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03908255 | Branched-chain Amino Acid Supplementation for Hepatocellular Carcinoma(BCAA in HCC) | Phase 2 | withdrawn | Apr 9, 2019 | Louisiana State University Health Sciences Center in New Orleans | Dr. Marshall left UMC and LSU Health Sciences Center. | Other (stated, no rule matched) |
| NCT04653389 | Perioperative Therapy for Hepatocellular Carcinoma | Phase 2 | terminated | Dec 4, 2020 | Zhejiang University | The treatment efficacy was not satisfactory. | Efficacy / futility |
| NCT04476329 | Optimization for Regorafenib in HCC(ReDos HCC) | Phase 2 | terminated | Jul 20, 2020 | SC Liver Research Consortium, LLC | Enrollment rate not sufficient to meet funding entity's corporation timeline expectations, entity… | Safety / toxicity |
| NCT01387932 | HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of…(HiQuality) | Phase 3 | terminated | Jul 6, 2011 | Merit Medical Systems, Inc. | The clinical study was terminated due to the inability to meet target enrollment. | Enrollment / accrual |
| NCT03071094 | A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic… | Phase 1 / Phase 2 | terminated | Mar 6, 2017 | Transgene | The decision was taken to stop prematurely the trial due to the failure of Pexa-Vec and nivolumab… | Other (stated, no rule matched) |
| NCT02304289 | Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Artesunate in…(DESPARTH) | Phase 1 | terminated | Dec 1, 2014 | University Hospital, Ghent | slow recruitment of patients | Enrollment / accrual |
| NCT01141478 | Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San…(HCC) | N/A | terminated | Jun 10, 2010 | Loma Linda University | due to low enrollment | Enrollment / accrual |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | Phase 1 | terminated | Sep 23, 2019 | Eli Lilly and Company | Study terminated due to strategic business decision by Eli Lilly and Company. | Sponsor / business decision |
| NCT04511793 | Hepatic Artery Infusion (HAI) Program at Duke University | N/A | withdrawn | Aug 13, 2020 | Michael Lidsky, M.D. | No subjects enrolled due to availability of device commercially. | Enrollment / accrual |
| NCT04947371 | Adjuvant Therapy With Anlotinib for HCC | Phase 2 | withdrawn | Jul 1, 2021 | Shanghai Zhongshan Hospital | The standard of care of adjuvant therapy for liver cancer was changed. | Other (stated, no rule matched) |
| NCT04479904 | A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic… | Phase 2 | withdrawn | Jul 21, 2020 | Jiangsu HengRui Medicine Co., Ltd. | It is difficult to screening subject | Other (stated, no rule matched) |
| NCT03203304 | Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer | Phase 1 | terminated | Jun 29, 2017 | University of Chicago | Study stopped due to poor accrual. | Enrollment / accrual |
| NCT01032850 | Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma | Phase 2 | terminated | Dec 16, 2009 | New Mexico Cancer Research Alliance | Low accrual rate | Enrollment / accrual |
| NCT03608878 | Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in HCC Patients With… | Phase 2 | terminated | Aug 1, 2018 | Chang Gung Memorial Hospital | The biopsies in the first 5 screened patients were all negative for Globo-H, of which positive is… | Other (stated, no rule matched) |
| NCT04264754 | Characterization of Methylation Patterns in Hepatocellular Carcinoma | — | terminated | Feb 11, 2020 | Nucleix Ltd. | Sponsor prioritize other clinical projects over this study | Other (stated, no rule matched) |
| NCT01887717 | Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the…(YES-P) | Phase 3 | terminated | Jun 27, 2013 | Boston Scientific Corporation | Poor Accrual. | Enrollment / accrual |
| NCT03452553 | Study in the Treatment of HCC With a Radiopaque (RO) Bead (LC Bead LUMI™) Loaded With… | N/A | withdrawn | Mar 2, 2018 | Boston Scientific Corporation | CMS disapproval, no alternative for sites/patient, risk of financial burden. | Funding |
| NCT03137706 | Characterization of Mechanical Tissue Properties in Patients With Pancreatic, Liver, or… | — | terminated | May 3, 2017 | University of Southern California | Insufficient accrual | Enrollment / accrual |
| NCT00892255 | Microwave Ablation of Resectable Liver Tumors | — | withdrawn | May 4, 2009 | St. Joseph Hospital of Orange | not stated | Not stated |
| NCT03563274 | QuiremSpheres Observational Study(Hope166) | — | terminated | Jun 20, 2018 | Terumo Europe N.V. | did not meet planned recruitment expectations with a slow recruitment rate | Enrollment / accrual |
| NCT04404647 | Irreversible Electroporation of Unresectable Liver Tumors | N/A | withdrawn | May 27, 2020 | Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery | Low accrual rate | Enrollment / accrual |
| NCT04526080 | Intrabucally Administered Electromagnetic Fields Versus Placebo as Third-line Therapy For…(TheraBionics) | Phase 2 | withdrawn | Aug 25, 2020 | Wake Forest University Health Sciences | This application needs further attention in terms of FDA approval and will be reassigned under a… | Other (stated, no rule matched) |
| NCT03303469 | Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo… | Phase 2 | terminated | Oct 6, 2017 | University of Alabama at Birmingham | study was terminated due to poor enrollment | Enrollment / accrual |
| NCT02129322 | Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1 | Phase 2 | withdrawn | May 2, 2014 | Zhejiang University | patients not enrolled | Enrollment / accrual |
| NCT02460991 | A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma(SOLACE) | Phase 3 | terminated | Jun 3, 2015 | Boston Scientific Corporation | Slow enrollment | Enrollment / accrual |
| NCT03008512 | A Phase II Study of Weekly Genexol-PM in Patients With Hepatocelluar Carcinoma After… | Phase 2 | terminated | Jan 2, 2017 | Gachon University Gil Medical Center | Poor accrual | Enrollment / accrual |
| NCT04398927 | Systemic Chemotherapy Plus PD-1 for Metastasis ICC | Phase 2 | withdrawn | May 22, 2020 | Sun Yat-sen University | no patient enrolled | Enrollment / accrual |
| NCT02524119 | LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma(LEE001) | Phase 2 | terminated | Aug 14, 2015 | University of Texas Southwestern Medical Center | This study was terminated after the sponsor withdrew our support | Other (stated, no rule matched) |
| NCT03219372 | Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence | Phase 2 | terminated | Jul 17, 2017 | Cedars-Sinai Medical Center | Study discontinued due to low accrual. | Enrollment / accrual |
| NCT00823290 | Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC) | Phase 1 | terminated | Jan 15, 2009 | University of Erlangen-Nürnberg Medical School | Investigator left site | Investigator |
| NCT00503867 | SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma | N/A | terminated | Jul 19, 2007 | Sirtex Medical | Low patient recruitment | Enrollment / accrual |
| NCT03040453 | Immunological Response After Ablative Therapy in the Liver(IRAL) | N/A | withdrawn | Feb 2, 2017 | Karolinska Institutet | poor recruitment | Enrollment / accrual |
| NCT04270461 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | Phase 1 | withdrawn | Feb 17, 2020 | Jiujiang University Affiliated Hospital | Study is withdrawn because of administrative reasons | Other (stated, no rule matched) |
| NCT02558205 | Correlation Between CT Perfusion and Post Y-90 TARE PET/CT Dosimetry | — | withdrawn | Sep 23, 2015 | Rush University Medical Center | unable to rectuir | Other (stated, no rule matched) |
| NCT02029690 | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With…(TRAP) | Phase 1 | terminated | Jan 8, 2014 | Polaris Group | not stated | Not stated |
| NCT04044326 | The Safety and Efficacy of Spherical Microwave Ablation for the Treatment of Malignant… | N/A | withdrawn | Aug 5, 2019 | National Taiwan University Hospital | Machine cannot provide | Other (stated, no rule matched) |
| NCT04546802 | HepATocellular Cancer Hcv Therapy Study(HATCHeT) | Phase 3 | withdrawn | Sep 14, 2020 | Bayside Health | Recruitment will be too difficult due to available PBS funded treatment and recent Australian… | Enrollment / accrual |
| NCT03203837 | Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere® | — | terminated | Jun 29, 2017 | Northwestern University | Funding Discontinued due to low accrual rate | Enrollment / accrual |
| NCT03644511 | Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent…(SORAGO-HCC) | — | terminated | Aug 23, 2018 | Bayer | The interest of potential centers is very limited. | Other (stated, no rule matched) |
| NCT03172559 | Radiotherapy Versus no Intervention in Adult Patients With Hepatocellular Carcinoma Not…(RADBRI) | N/A | withdrawn | Jun 1, 2017 | University Health Network, Toronto | Investigator decided not to pursue the study due to other competing studies. | Investigator |
| NCT03511222 | Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors | Phase 1 | terminated | Apr 27, 2018 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT04395118 | STOP HCC: Mailed HCV Treatment Outreach Program for HCC Prevention for Elevated LFTs(STOP-HCC) | N/A | withdrawn | May 20, 2020 | University of Texas Southwestern Medical Center | Study will not be conducted as a RCT due to limited project timeline. | Other (stated, no rule matched) |
| NCT02989870 | Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma | Phase 1 | withdrawn | Dec 12, 2016 | H. Lee Moffitt Cancer Center and Research Institute | No Interest. Investigator was unable to enroll any participants on study. | Investigator |
| NCT03480152 | Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by… | Phase 1 / Phase 2 | terminated | Mar 29, 2018 | National Cancer Institute (NCI) | slow accrual | Enrollment / accrual |
| NCT03801499 | Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma | Phase 2 | withdrawn | Jan 11, 2019 | Sun Yat-sen University | Protocol modification | Other (stated, no rule matched) |
| NCT04093648 | T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor… | Phase 1 | withdrawn | Sep 18, 2019 | Baylor College of Medicine | The key elements of this study were incorporated into another study. | Other (stated, no rule matched) |
| NCT01486134 | Major RF Ablations of Hepatomas Under MR Thermometry Monitoring(ARMTICH) | N/A | terminated | Dec 6, 2011 | Assistance Publique - Hôpitaux de Paris | For technical reasons | Other (stated, no rule matched) |
| NCT02013778 | Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC | Phase 1 / Phase 2 | terminated | Dec 17, 2013 | Abramson Cancer Center at Penn Medicine | Lack of enrollment | Enrollment / accrual |
| NCT03748927 | Natural History Study of Children and Adults With Fibrolamellar Hepatocellular Carcinoma | — | withdrawn | Nov 21, 2018 | National Cancer Institute (NCI) | slow/insufficient accrual | Enrollment / accrual |
| NCT03990974 | Postoperative Antimicrobial Prophylaxis Versus Placebo for Infection Prevention in HCC…(HCC) | Phase 3 | suspended | Jun 19, 2019 | Sun Yat-sen University | There were difficulties in implementation | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jan 28, 2022source: clinicaltrials